UroGen Pharma Ltd. (URGN) is a publicly traded, clinical-stage biopharmaceutical company dedicated to developing novel therapies designed to change the standard of care for urological pathologies. The company was founded in 2006 with a primary focus on uro-oncology. It is headquartered in Ra'anana, Israel, with U.S. operations based in Princeton, New Jersey, and maintains a public listing on the NASDAQ stock exchange under the symbol "URGN".
UroGen Pharma utilizes its proprietary RTGelTM reverse-thermal hydrogel technology platform to propel the development and commercialization of its product portfolio. This platform allows therapeutic agents to remain in contact with targeted tissues for longer durations, potentially enhancing the treatment effectiveness of existing drugs.
UroGen's lead product, UGN-101 (Mitomycin gel, also known as Jelmyto), is a first-of-its-kind therapeutic approach for the treatment of low-grade upper tract urothelial cancer (LG UTUC). It received approval from the U.S. Food and Drug Administration (FDA) in April 2020, marking a significant milestone for the company. Prior to this, no drugs were approved specifically for LG UTUC, and surgical options often led to significant morbidity.
In addition to UGN-101, UroGen is developing UGN-102 (mitomycin gel), a potentially non-surgical outpatient treatment for low-grade non-muscle invasive bladder cancer (LG NMIBC). This product is currently in phase IIb clinical trials.
UroGen Pharma is led by a team of seasoned professionals with notable expertise in urology, oncology, and drug development. The company is committed to improving the lives of patients by breaking new ground in urologic care and delivering results through relentless scientific and clinical execution.
With its innovative product pipeline and commercialization of its unique platform, UroGen Pharma Ltd. continues to position itself as a leader in providing solutions for overlooked and underserved urological conditions. Through its relentless commitment towards finding innovative solutions for these illnesses, UroGen Pharma Ltd. aims to revolutionize the healthcare system's approach towards urological disorders.
Despite being relatively young, UroGen’s achievements, fuelled by its commitment to excellence and a disruptive approach towards developing solutions, have distinguished it within the biopharmaceutical industry. The future holds promise as UroGen Pharma continues to develop its product pipeline and build on its successes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
UroGen Pharma (URGN) is an oncology and urology therapeutics company focused on localized drug delivery systems. The company recently announced an agreement with IntraGel Therapeutics for new oncology products and an investment in their equity, leveraging its strong commercial performance from ZUSDURI, which saw significant revenue growth in Q2 2026. While UroGen shows pipeline expansion and strong commercial results, the market remains somewhat skeptical, as indicated by short interest and a high forward earnings multiple, reflecting a divided view on its growth prospects.
_07_03_2026_03_50_21_133108.jpg)
Jason Drew Smith, General Counsel of UroGen Pharma Ltd. (NASDAQ: URGN), reported the vesting of 3,334 restricted stock units (RSUs) on September 7, 2026. Following this, he sold 1,519 ordinary shares at $42.54 each on September 8, 2026, to cover tax liabilities. Smith now directly owns 53,141 ordinary shares after these transactions.
UroGen Pharma has transitioned into a commercial-stage biopharma with the strong adoption of Zusduri for recurrent non-muscle-invasive bladder cancer, achieving an 80% complete response rate in the ENVISION trial. The company is also progressing with URGN-103, a next-generation product, which has completed NDA submission. Despite a short cash runway and execution risks, the article maintains a "Buy" rating on URGN stock due to robust early commercial execution and significant market potential.
This article provides an AI-generated analysis of Urogen Pharma Ltd. (NASDAQ: URGN), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss points. The analysis emphasizes an exceptional risk-reward short setup and provides multi-timeframe signal analysis for different investment horizons.
UroGen Pharma (URGN) recently submitted a New Drug Application to the FDA for UGN-103, backed by strong Phase 3 trial data, which has led to significant share price appreciation. Despite this momentum and a positive outlook for their minimally invasive therapies, Simply Wall St's analysis suggests the stock might be overvalued at its current price of $46.86 compared to a fair value of $36.11, though other metrics like P/S ratio present a more balanced picture. The company's future performance hinges on successful product uptake and avoiding trial setbacks, given its reliance on a narrow product set and current operating losses.